Patient Square Capital’s Dianthus Therapeutics DNTH Stock Holding History

Patient Square Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5M	Buy	108,000 +14,118	+15%	+$1.23M	1.63%	16
2026 Q1	$7.88M	Sell	93,882 -56,118	-37%	-$3.25M	1.4%	20
2025 Q4	$6.18M	Buy	150,000 +25,000	+20%	+$969K	1.32%	16
2025 Q3	$4.92M	Buy	+125,000	New	+$3.19M	1.32%	15

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Patient Square Capital's DNTH Position: Q2 2026 in Review

Patient Square Capital increased its Dianthus Therapeutics (DNTH) stake by 15% in Q2 2026, buying an estimated $1.23M and bringing the position to 108,000 shares worth $10.5M. The position accounts for 1.63% of the portfolio, ranked #16.

Patient Square Capital first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Patient Square Capital held 108,000 shares of Dianthus Therapeutics worth $10.5M as of Q2 2026.
Patient Square Capital bought 14,118 Dianthus Therapeutics shares in Q2 2026, an estimated $1.23M.
Dianthus Therapeutics made up 1.63% of Patient Square Capital's portfolio in Q2 2026, its #16 holding.
Patient Square Capital first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.